EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Active Compounds, Targets, and Mechanisms of Salvia miltiorrhiza Bunge in Treating Interstitial Cystitis/Bladder Pain Syndrome

Liang Wang iD, Bei Yu, YaRong Wang, Xi Qu, Wei Tang

Immunity, Inflammation and Disease · 2025

DOI: 10.1002/iid3.70173 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, 2025. Verfasst von Liang Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Cystitis, Interstitial, Salvia miltiorrhiza. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the active compounds, molecular targets, and biological mechanisms of Salvia miltiorrhiza Bunge (SM) in treating interstitial cystitis/bladder pain syndrome (IC/BPS) through network pharmacology and a cyclophosphamide‐induced cystitis model.

Methods

A network pharmacology approach was used to assess the effects of SM and luteolin in IC/BPS. Female C57BL/6 mice were divided into four groups: CON, CON + Luteolin, CYP, and CYP + Luteolin, with luteolin (100 mg/kg) administered for CYP‐induced cystitis. Histological and molecular analyses, including H&E staining, TUNEL, ELISA, Western blot, and urodynamics, were performed to explore the mechanisms.

Results

Network pharmacology showed 65 active ingredients and 148 potential targets of SM in the treatment of IC/BPS, of which luteolin had the highest potential. TP53, AKT1, CCND1, EGFR, and ERBB2 are the core targets, and PI3K‐Akt and p53 are important signaling pathways for luteolin in the treatment of IC/BPS. Compared with the CYP group, the CYP + Luteolin group showed significantly lower bladder tissue scores; reduced expression of malondialdehyde, inflammatory factors (IL‐18, IL‐1β, IL‐6), and apoptosis‐related proteins (cleaved‐Caspase‐3, Bax, cleaved‐Caspase‐8); significantly increased expression of total SOD and glutathione; and improved bladder function. Animal experiments have shown that luteolin can block the activation of the PI3K‐Akt and p53 signaling pathways.

Conclusion

SM has a variety of potentially active components for the treatment of IC/BPS, of which luteolin has the highest potential. Luteolin can inhibit inflammation, oxidative stress, and apoptosis through the p53 and PI3K‐Akt signaling pathways and plays a role in treating IC/PBS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystitis, InterstitialSalvia miltiorrhizaAnimalsFemaleMiceMice, Inbred C57BLDisease Models, AnimalSignal TransductionCyclophosphamideLuteolinNetwork PharmacologyApoptosisOxidative StressUrinary Bladder

Stichwörter der Autor:innen

PI3K‐Akt signaling pathwaysSalvia miltiorrhiza Bungeinterstitial cystitis/bladder pain syndromeluteolinnetwork pharmacologytarget

Substanzen

CyclophosphamideLuteolin

Autor:innen und Institutionen

  • Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

ORCID-Profile: Liang Wang

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Wang, L., Yu, B., Wang, Y., Qu, X., & Tang, W. (2025). Active Compounds, Targets, and Mechanisms of Salvia miltiorrhiza Bunge in Treating Interstitial Cystitis/Bladder Pain Syndrome. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.70173

Vancouver

Wang L, Yu B, Wang Y, Qu X, Tang W. Active Compounds, Targets, and Mechanisms of Salvia miltiorrhiza Bunge in Treating Interstitial Cystitis/Bladder Pain Syndrome. Immunity, Inflammation and Disease. 2025. doi:10.1002/iid3.70173

BibTeX
@article{Wang2025,
  author = {Wang, Liang and Yu, Bei and Wang, YaRong and Qu, Xi and Tang, Wei},
  title = {Active Compounds, Targets, and Mechanisms of Salvia miltiorrhiza Bunge in Treating Interstitial Cystitis/Bladder Pain Syndrome},
  journal = {Immunity, Inflammation and Disease},
  year = {2025},
  doi = {10.1002/iid3.70173}
}
Kostenlos starten →